Monday
March 24, 2025
8:05 AM ET
Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands
Tuesday
February 25, 2025
7:30 AM ET
Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs
Wednesday
February 19, 2025
8:05 AM ET
Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia
Tuesday
February 18, 2025
8:05 AM ET
Harmony Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
Monday
January 13, 2025
8:05 AM ET
Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts
Tuesday
October 29, 2024
7:30 AM ET
HARMONY BIOSCIENCES REPORTS STRONG THIRD QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS CATALYST-RICH, LATE-STAGE PIPELINE POISED TO DELIVER ONE OR MORE NEW LAUNCHES EVERY YEAR OVER NEXT FIVE YEARS
Wednesday
October 16, 2024
8:05 AM ET
HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2024 FINANCIAL RESULTS ON OCTOBER 29, 2024